Evaluation the preventive effects of purgative manna on neonate’s icter in Sanandaj, Iran

Preventive effects of purgative manna (vs. placebo) on neonate’s icter

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138901223666N2

Enrollment

140

Registered

2010-11-26

Start date

2009-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal icterus. Neonatal jaundice from other and unspecified causes

Interventions

Intervention 1: Intervention: Bilinaster drop produced by Sobhan Co. oral 5 drop/TDS (Twenty four hours after birth, for three days). Intervention 2: Control: Placebo drop produced by Sobhan Co. oral

Treatment - Drugs

Control: Placebo drop produced by Sobhan Co. oral 5 drop/TDS

Intervention: Bilinaster drop produced by Sobhan Co. oral 5 drop/TDS (Twenty four hours after birth, for three days)

Eligibility

Sex/Gender

All

Age

1 Years to 3 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Full term neonate. Exclusion criteria: Congenital anomalies, Icter in day 1

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Icterus. Timepoint: Day 3-5. Method of measurement: clinical examination and Lab exam.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Majid Mansouri

Kurdistan University of medical sciences

Magidmansoori@Yahoo.com+98 87 1324 7594

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026